Triple receptor-negative breast cancer (TNBC) is a complex heterogeneous disease that carries a worse prognosis and tends to relapse earlier than other subtypes of breast cancer. Until very recently, the options for treating a patient with TNBC were limited to chemotherapy combined with surgery or radiation, as indicated. However, new and emerging targeted therapies offer hope that more effective treatments and better outcomes will be available for these patients. This program examines the efficacy of current, new, and emerging therapies, their potential role in treatment, and ways to manage their toxicities and adverse events.
eNewsletter with interactive benchmarking and audio commentary
To provide clinicians with a greater understanding of the biology of TNBC and novel and emerging agents being developed to treat it
After completing this activity, participants should be better able to:
- Identify the mechanisms of action of novel and emerging therapies for TNBC
- Summarize evidence for the efficacy of new and emerging therapies for TNBC and their potential role in the treatment regimen
- Develop strategies to monitor, recognize, and manage adverse events associated with the treatment of TNBC
Oncology NPs, PAs, and nurses
CNE Credit Designation Statement
In support of improving patient care, Continuing Education Alliance is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Nursing contact hours: 1.00, which includes 1.00 hours of pharmacology credit
Nurse Planner: Katie Zahasky, NP
PA Planner: Heather M. Hylton, PA
AAPA Credit Designation Statement
Continuing Education Alliance has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until April 30, 2020. PAs should only claim credit commensurate with the extent of their participation.
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This activity is supported by an educational grant from Celgene.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Continuing Education Alliance, Practicing Clinicians Exchange, or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Continuing Education Alliance are required to disclose to the audience any relevant support or substantial relationships with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and planning committee have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr Tolaney: advisory board/consultant/grant/research support: AstraZeneca, Eisai, Lilly, Merck, Nanostring, Nektar, Novartis, Pfizer; advisory board: Celldex, Immunomedics, Puma, Sanofi; advisory board/grant/research support: Genentech/Roche; consultant: Tesaro; grant/research support: Bristol-Myers Squibb, Cyclacel, Exelixis.
None of the members of the Planning Committee or CE Alliance staff have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- Read the content in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form online
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 70%.
The estimated time to complete this activity is 1.00 hours.
Release date: April 30, 2019
Expiration date: April 30, 2020
© 2020 Practicing Clinicians Exchange. All Rights Reserved. CGPCE96019